{"title":"Engineering biocompatible carbon dots nano-enzymes hydrogel for efficient antioxidative and anti-inflammatory treatment of dry eye disease","authors":"Hailing Yu , Xinxi Yu , Yin Huang , Ting Yu , Huimin Lan , Qianqian Zhang , Yongquan Huang , Xin Peng , Zebo Jiang","doi":"10.1016/j.jconrel.2025.01.081","DOIUrl":null,"url":null,"abstract":"<div><div>Dry eye disease (DED) is a complex and multifactorial ocular surface disease. Reactive oxygen species (ROS) are of pivotal importance in the inflammatory processes and biological dysfunction associated with DED. In this study, an injectable hydrogel, designated as OHACDgel, was created by combining oxidized HA-containing aldehyde groups (OHA) and gelation (gel) <em>via</em> dynamic covalent linkages of the hydrazine bonds, is employed as the carrier, while polyethylene imine-functionalized carbon dots (PEI-CD) can form dynamic chemical bonds with the hydrogel, thus prolonging the retention time of the ocular surface. OHACDgel has been demonstrated to diminish ROS overproduction markedly, reduce the expression of pro-inflammatory factors, inhibit the transformation of macrophages into a pro-inflammatory phenotype, reverse corneal epithelial defects, restore goblet cell function, and enhance tear secretion. Furthermore, the biocompatibility of OHACDgel has been demonstrated, presenting a rapid and straightforward therapeutic option for potential applications in DED.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"381 ","pages":"Article 113490"},"PeriodicalIF":10.5000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Controlled Release","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168365925000914","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Dry eye disease (DED) is a complex and multifactorial ocular surface disease. Reactive oxygen species (ROS) are of pivotal importance in the inflammatory processes and biological dysfunction associated with DED. In this study, an injectable hydrogel, designated as OHACDgel, was created by combining oxidized HA-containing aldehyde groups (OHA) and gelation (gel) via dynamic covalent linkages of the hydrazine bonds, is employed as the carrier, while polyethylene imine-functionalized carbon dots (PEI-CD) can form dynamic chemical bonds with the hydrogel, thus prolonging the retention time of the ocular surface. OHACDgel has been demonstrated to diminish ROS overproduction markedly, reduce the expression of pro-inflammatory factors, inhibit the transformation of macrophages into a pro-inflammatory phenotype, reverse corneal epithelial defects, restore goblet cell function, and enhance tear secretion. Furthermore, the biocompatibility of OHACDgel has been demonstrated, presenting a rapid and straightforward therapeutic option for potential applications in DED.
期刊介绍:
The Journal of Controlled Release (JCR) proudly serves as the Official Journal of the Controlled Release Society and the Japan Society of Drug Delivery System.
Dedicated to the broad field of delivery science and technology, JCR publishes high-quality research articles covering drug delivery systems and all facets of formulations. This includes the physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development across pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries.
Priority is given to manuscripts that contribute to the fundamental understanding of principles or demonstrate the advantages of novel technologies in terms of safety and efficacy over current clinical standards. JCR strives to be a leading platform for advancements in delivery science and technology.